1John P,Eila C,Stuart D,et al.Squamous cell Carcinoma of the bladder associated with cyclophosphamide therapy for wegener's granulomatosis:a report of 2 Cases[J].J Urol,1992,149:588 ～ 589.
2Worth PH.Cyclophosphamide and the bladder:letter to the Editor[J].Brit Med J,1971,3:182.
3Brock N.Pharmacologic characterization of cyclophosphamide (NSC-26271) and cyclophosphamide metabolites[J].Cancer Chemother Rep,1967,15:315.
4Brock N,Steker J,Pohl J,et al.Acrolein the causative factor of urotoxic side effects of cyclophosphamide if osfamide trofosfamide and sufosfamide[J].Arzneim Forch,1979,29:659 ～ 661.
5Habs MR.Schmahl D.Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectoos sodium 2-mercaptoethane sulfonate (mesna) and disodium2.2-dithiobis ethane sulfonute (dimesna)[J].Cancer,1983,51:606 ～ 609.
6Gary L,Baker MD,Leslie E,et al.Malignancy following treatment of rheumatoid arthritis with cyclophosphamide[J].Am J Med,1987,83:1 ～ 9.
7Harold S,John E,Tomaszewski DM,et.al.Carcinosarcoma of bladder following long-term cyclophosphamide therapy[J].Arch Pathol Med,1991,115:1049～1051.
8Eduardo T,Fernandes J,Pratap K,et al.Cyclophosphamide associated bladder cancer a highly aggressive disease:analysis of 12 cases[J].J Urol,1996,156.1931～1933.
9Vanhcefer U,Schleucher N,Klaassen U,et al.Ifosfamide based drug combination:preclinical evaluation of drug interactions and translation into the clinic[J].Semin Oncol,2000,27(lsupple):8 ～ 11.
10Huang Z,Roy P,Waxman DJ,Role of human liver microsomal CYP3A4 and CYP206 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide[J].Biochem Pharmcol,2000,59:961.
4ZHANG Y, WU G, HU X, et al. Effect of cyclophosphamide on expression of MMP-9 and TGF 171 in renal tissue of rats with diabetes mellitus[J]. Cell Bioehem Biophys, 2015, 72 (2) : 399 403.
5PEARSON RM, SOLOWAY MS. Does cyclophosphamide in duce bladder cancer? [J]. Urology,1978,11(5) 437-447.
6HABS MR, SCHMAHLD. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectoos sodium 2-mercaptoethane sulfonate (mes- ha) and disodiurn2. 2-dithiohis ethane sulfonute(dimesna) [J]. Cancer, 1983,51 (4) : 606-609.
7潘世纶.环磷酰胺可能致膀胱癌[J].日本医学介绍,1990,11(6):282.
8PEREZ AA, BALABRAM D, ROCHA RM, et al. Co-expres- sion of p16, Ki67 and COX-2 is associated with basal phenotype in high-grade ductal carcinoma in situ of the breast[J]. J Histo- chem Cytochem, 2015, 63(6) :408-416.
9VANHOEFER U, SCHLEUCHER N, KLAASSEN U, et al. Ifosfamide-based drug combination : preclinical evaluation of drug interactions and trans-lation into the eli nic[J]. Semin On- col, 2000,27(1) : 8-13.
10RASMUSSEN MA, HOLST B, TUMER Z, et al. Transient p53 suppression increases reprogramming of human {ibroblasts without affecting apoptosis and DNA damage[J]. Stem Cell Re- ports, 2014, 3(3) 404-413.
